Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
INTS
Upturn stock ratingUpturn stock rating

Intensity Therapeutics, Inc. Common stock (INTS)

Upturn stock ratingUpturn stock rating
$0.3
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: INTS (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $3.33

1 Year Target Price $3.33

Analysts Price Target For last 52 week
$3.33 Target price
52w Low $0.19
Current$0.3
52w High $4.35

Analysis of Past Performance

Type Stock
Historic Profit -60.26%
Avg. Invested days 33
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 14.05M USD
Price to earnings Ratio -
1Y Target Price 3.33
Price to earnings Ratio -
1Y Target Price 3.33
Volume (30-day avg) 5
Beta 3.78
52 Weeks Range 0.19 - 4.35
Updated Date 08/15/2025
52 Weeks Range 0.19 - 4.35
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.82

Earnings Date

Report Date 2025-08-07
When -
Estimate -0.16
Actual -0.13

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -122.68%
Return on Equity (TTM) -334.12%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 11555740
Price to Sales(TTM) -
Enterprise Value 11555740
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -4.72
Shares Outstanding 47057700
Shares Floating 40822108
Shares Outstanding 47057700
Shares Floating 40822108
Percent Insiders 13.25
Percent Institutions 5.54

ai summary icon Upturn AI SWOT

Intensity Therapeutics, Inc. Common stock

stock logo

Company Overview

overview logo History and Background

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel, targeted cancer immunotherapies. Founded to improve outcomes for patients with difficult-to-treat cancers, the company leverages its proprietary DfuseRxSM technology platform.

business area logo Core Business Areas

  • Drug Development: Research and development of novel cancer therapies using the DfuseRxSM platform, focusing on intratumoral injections to deliver potent anti-cancer agents directly into tumors.

leadership logo Leadership and Structure

Lewis H. Bender serves as the Chief Executive Officer and President. The company has a board of directors and a management team overseeing research, development, and clinical trials.

Top Products and Market Share

overview logo Key Offerings

  • INT230-6: INT230-6 is Intensity Therapeutics' lead product candidate, an investigational product designed for direct intratumoral injection. It is being evaluated in Phase 1/2 clinical trials for advanced solid tumors. Market share information is not currently available as this is an investigational drug. Competitors in immuno-oncology include major pharmaceutical companies like Merck (MRK), Bristol Myers Squibb (BMY), and Roche (RHHBY).

Market Dynamics

industry overview logo Industry Overview

The oncology market is experiencing rapid growth, driven by advancements in immunotherapy and targeted therapies. There is a significant unmet need for effective treatments for patients with advanced and resistant cancers.

Positioning

Intensity Therapeutics aims to differentiate itself through its DfuseRxSM platform, which allows for direct delivery of anti-cancer agents into tumors, potentially enhancing efficacy and reducing systemic toxicity.

Total Addressable Market (TAM)

The global oncology market is estimated at hundreds of billions of dollars. Intensity Therapeutics aims to capture a portion of this market by addressing difficult-to-treat cancers through its innovative approach.

Upturn SWOT Analysis

Strengths

  • Proprietary DfuseRxSM platform
  • Targeted intratumoral drug delivery
  • Potential for enhanced efficacy and reduced toxicity
  • Experienced management team

Weaknesses

  • Limited financial resources
  • Early-stage clinical development
  • Reliance on a single lead product candidate
  • High risk of clinical trial failure

Opportunities

  • Positive clinical trial results
  • Strategic partnerships with larger pharmaceutical companies
  • Expansion into new cancer indications
  • Potential for breakthrough therapy designation

Threats

  • Competition from established immuno-oncology therapies
  • Regulatory hurdles and delays
  • Unfavorable clinical trial outcomes
  • Difficulty securing financing

Competitors and Market Share

competitor logo Key Competitors

  • Merck (MRK)
  • Bristol Myers Squibb (BMY)
  • Roche (RHHBY)

Competitive Landscape

Intensity Therapeutics faces intense competition from established pharmaceutical companies with significantly greater resources. Its competitive advantage lies in its novel DfuseRxSM platform, which could potentially offer a differentiated approach to cancer immunotherapy.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is measured by progress in clinical trials and milestones achieved in drug development.

Future Projections: Future growth is dependent on the success of clinical trials and regulatory approvals. Analyst estimates vary widely given the inherent risks in drug development.

Recent Initiatives: Recent initiatives include enrollment in ongoing clinical trials for INT230-6 and presentations at medical conferences.

Summary

Intensity Therapeutics is a clinical-stage company focused on innovative cancer therapies using its DfuseRxSM platform. The company faces significant challenges, including competition from larger pharmaceutical companies and the inherent risks of drug development. Positive clinical trial results and strategic partnerships are critical for the company's future success. The focus on difficult to treat tumors sets them apart from the normal cancer therapeutics.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Intensity Therapeutics' website
  • SEC filings
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Investing in biotechnology companies carries significant risk.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Intensity Therapeutics, Inc. Common stock

Exchange NASDAQ
Headquaters Shelton, CT, United States
IPO Launch date 2023-06-30
Founder, President, CEO & Chairman of the Board Mr. Lewis H. Bender M.A., M.B.A., M.S.
Sector Healthcare
Industry Biotechnology
Full time employees 5
Full time employees 5

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.